Ciresi A, et al. - The effectiveness of liraglutide in reducing the Framingham risk score (FRS) and visceral adiposity index (VAI) was evaluated in relation to first-line hypoglycemic treatment from diagnosis of type 2 diabetes, continued without any changes. The authors revealed that in reducing cardiovascular risk, liraglutide was more efficacious than when it was used as add-on therapy to the first-line therapy from diagnosis with metformin and not with insulin secretagogues, during a 48-month follow-up.